Drugs / allogeneic hematopoietic stem cells
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01852370 | Jun 2013 → Nov 2026 expected | Wiskott-Aldrich syndrome, chronic granulomatous disease, common variable immunodeficiency, hyper-IgE syndrome +3 | Paul Szabolcs | Enrolling by invitation | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT01782287 | Dec 2012 → Dec 2018 | metastatic neoplasm | NeuroVita Clinic | Unknown | No outcome recorded |
| Phase 2/3 | NCT01782274 | Dec 2012 → Dec 2018 | metastatic neoplasm | NeuroVita Clinic | Unknown | No outcome recorded |
| Phase 2/3 | NCT01759810 | Dec 2012 → Dec 2018 | glioblastoma | NeuroVita Clinic | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | allogeneic hematopoietic stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01782287 ↗ |
| Action | Deplete | “HSCs are used to stimulate individualized adoptive immune response, to affect tumor cells (TCs) toxically” NCT01782287 ↗ |
| Modality | Cell therapy | “allogeneic hematopoietic stem cells” NCT01759810 ↗ |
| Route | Intrathecal | “3 ml suspension of allogeneic hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace” NCT01759810 ↗ |